Exclusive Summary

• Differentiated Mechanism & Best-in-Class Potential: UB520 is a novel, highly selective liver-targeting THR-β prodrug that utilizes a one-step hydrolysis mechanism, bypassing the CYP oxidation pathway to significantly minimize DDI (drug-drug interaction) risks and individual variations.
• Directly Addresses Core GLP-1 Limitations: As a monotherapy, it achieves weight loss comparable to semaglutide but with a breakthrough 'muscle preservation' advantage (an impressive 15:1 fat-to-lean mass loss ratio) and minimal appetite suppression, solving the GI and muscle-wasting issues of current standard cares.
• Highly Versatile Combo Strategy: Substantial in vivo studies demonstrate that UB520 works synergistically with injectable GLP-1s (Semaglutide, Tirzepatide) and oral GLP-1s (Orforglipron), accelerating weight loss, boosting lipid reduction, and further preserving lean mass.
• Superior Liver Targeting and Cardiac Safety: Compared to late-stage competitor VK-2809, UB520's active metabolite demonstrates significantly higher liver accumulation and a superior liver/heart ratio, effectively mitigating potential off-target cardiovascular risks.